STAT+: Pharmalittle: Pfizer to boost Covid-19 vaccine production; HHS overrules FDA on its top lawyer pick
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
Category: STAT+
STAT+: With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Verve Therapeutics said Tuesday its one-time treatment that uses the “base editing” form of CRISPR…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2019
During 2019, drug makers raised prices on seven widely used medicines by substantial amounts without…
STAT+: In a last-minute, intra-agency scuffle, HHS overrules FDA pick for a key position
WASHINGTON — Health secretary Alex Azar suddenly appointed a new top lawyer at the Food…
.jpg)
STAT+: Gilead’s remdesivir sales are surging, but investors aren’t impressed
A lot more Covid-19 patients in the U.S. are being treated with Gilead Sciences’ remdesivir…
STAT+: Commerce Department agency proposes eliminating ‘march-in rights’ as a tool to lower drug prices
In a little-noticed move, a Commerce Department unit has proposed a new rule that would…
STAT+: A Covid-19 vaccine maker in India stirs controversy over its clinical trial
For the second time in two weeks, patient groups in India are raising concerns about…
STAT+: Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value
Biogen added more than $4 billion in market value on Monday after a rival Alzheimer’s…
STAT+: Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research…
STAT+: Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for…
STAT+: Pharmalittle: Lilly says Alzheimer’s drug may slow cognitive decline; half-dose of AstraZeneca Covid-19 shot may not work
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Tempus unveils prototype cube that talks back to oncologists
Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube,…
STAT+: Eli Lilly says drug slowed Alzheimer’s decline in preliminary study
An experimental medicine appeared to slow the decline of patients with the early symptoms of…
STAT+: Democrats have their best shot yet at letting Medicare negotiate drug prices — but it’s still not a done deal
WASHINGTON — Democrats have their best shot in more than a decade to deliver on…
STAT+: Tennessee to become the first state to run a closed Medicaid drug formulary
In a first-of-its-kind move, the Trump administration will allow Tennessee officials to restrict medicines covered…
STAT+: FDA advisory panel meetings became ‘rarer and tougher’ in 2020
Among the myriad changes wrought by the Covid-19 pandemic, Food and Drug Administration advisory committee…
STAT+: ‘What was left for Haven?’: How Amazon’s health ambitions devoured Haven’s plans
It’s tempting to see Haven as another casualty of entrenched interests in American medicine. But…
STAT+: Pharmalittle: Pfizer-BioNTech vaccine seems to work against Covid-19 mutation; Sarepta gene therapy shows mixed results
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
Sarepta Therapeutics on Thursday announced mixed results from the first randomized clinical trial of its…
STAT+: With success in vaccines, scientists try to turn mRNA against autoimmune diseases
The technology used in a pair of pioneering Covid-19 vaccines works by effectively revving up…
.jpg)
STAT+: With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
Just over two months after announcing its debut with $108 million in funding, Boston startup…
STAT+: Pharmalittle: Slaoui to become Warp Speed consultant; CureVac teams with Bayer for Covid-19 vaccine help
Good morning, everyone, and how are you today? Like many others, we are forging ahead…
Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
John Hood is at it again. In 2016, Hood started a company, Impact BioMedicines, around…
STAT+: Generic drug makers fear a ‘skinny labeling’ court ruling will pose a huge threat
An arcane regulatory term known as skinny labeling may have a funny ring to it,…
STAT+: Pharmalittle: U.S. speeds plan for pharmacies to give Covid-19 shots; European agency okays Moderna vaccine
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors
Almost five years after debuting his first biotech company, noted writer and oncologist Siddhartha Mukherjee…
STAT+: Pharmalittle: FDA warns against changing Covid-19 vaccine dosing; Moderna to increase vaccine production
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: Inside the collapse of a disrupter: How Haven’s high hopes of redefining health care came to a crashing halt
The dissolution of Haven marks one of the most stunning collapses in modern health care…
STAT+: Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?
In a typical year, a biotech startup might hope to raise enough money to keep…
STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first…
STAT+: Pharma rings in the new year with 5% price hikes on hundreds of medicines
When it comes to prescription drug prices, what goes up often continues to go up…
STAT+: HHS rebukes drug makers for curtailing discounts to hospitals that serve low-income communities
After months of controversy, the Department of Health and Human Services issued a stern rebuke…
STAT+: Pharmalittle: U.S. considers giving half-doses of Moderna vaccine; Americans may not get AstraZeneca shot until April
Good morning, everyone, and nice to see you after an extended holiday break. We hope…
STAT+: The health tech tracker for the first quarter: 13 important events to watch
It will be a quarter unlike any other in recent memory for the health tech…
STAT+: The biotech 2021 preview, from M&A to gene therapy and more
Hello, Biotech 2021. In the interest of humility, we’ll note that last year’s preview story…
STAT+: Indian regulators are pushed to release Covid-19 vaccine trial protocol
As Indian regulators consider emergency approval of a Covid-19 vaccine from the Serum Institute of…
STAT+: 3 pharma trends to watch in 2021
To say this past year has been like no other is an understatement. But for…
STAT+: 3 freshman lawmakers for health wonks to watch
WASHINGTON — Members of Congress have a habit of contorting their resumes to find a…
STAT+: 3 biotech trends to watch
For biotech companies, 2020 could have been a lot worse than it was, all things…
STAT+: 3 key questions for the health tech industry in 2021
Fueled by a seemingly endless influx of cash, technology has influenced the practice of medicine…
STAT+: 3 Biden staffers to watch in 2021
WASHINGTON — President-elect Biden is set to take office Jan. 20, and he’s made repeatedly…
Opinion: STAT+: ‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well
With the Moderna vaccine, Massachusetts is having a moment. Ours is a story not about…
STAT+: Federal judge places restraining order on Trump’s latest drug pricing rule
WASHINGTON — A federal judge on Wednesday issued a temporary restraining order preventing one of…
STAT+: Pharmalittle: Feds sue Walmart over opioid prescriptions; U.S. buys more Pfizer vaccine doses
Good morning, everyone. Damian Garde here, filling in for Ed Silverman one last time as…
STAT+: How 2020 became the year of the biotech SPAC
Over the past year, the humble blank-check IPO has risen from a disreputable relic of…
STAT+: Pharmalittle: EU clears Pfizer’s Covid-19 vaccine; Americans are increasingly willing to get the shot
Good morning, everyone. Damian Garde here, filling in for Ed Silverman once more in the…
STAT+: The most impressive biotech VCs of 2020
Behind almost every biotech IPO, every merger, and every buyout are a set of venture…
STAT+: Health tech’s newest unicorn is running toward Medicaid patients long marginalized in medicine
It has become a business imperative in American medicine to marginalize patients on Medicaid. Their…
STAT+: Pharmalittle: Moderna’s Covid-19 vaccine rolls out across the U.S.; FDA rejects Novartis cholesterol drug
Good morning, one and all. Damian Garde here, filling in for Ed Silverman on this…
STAT+: Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient
UniQure, the Dutch gene therapy company, said Monday that it had temporarily halted the clinical…